NJEC(SH:600699) Xuan Gu Bao·2025-09-04 12:06Group 1: Stock Suspension and Resumption - Zhonghuan Hailu has terminated the planning of a change in company control, and its stock has resumed trading [1] Group 2: Mergers and Acquisitions - China Shipbuilding Industry Corporation will conduct a share swap to absorb China Shipbuilding Heavy Industry Company, with the latter's A-shares set to be delisted on September 5 [2] - Kebo Da plans to acquire 60% equity of Kebo Da Intelligent Technology from Shanghai Keshishi for 345 million yuan, which constitutes a related party transaction. The target company focuses on providing high-performance automotive intelligent central computing platforms and related domain controllers [2] Group 3: Investment Cooperation and Operational Status - Junsheng Electronics has collaborated with leading clients such as Zhiyuan Robotics and Galaxy General, achieving mass supply of customized main control boards and various sensors, as well as developing customized battery packs and high-power wireless charging products [3] - Beijing Lier has signed strategic cooperation agreements with SenseTime and Xiwang Technology to explore AI computing power collaboration [4] - Guoxin Technology has successfully tested a new generation of high-performance chips for automotive electronic BLDC motor drive control [5] - Jifeng Technology plans to establish a wholly-owned subsidiary, Jifeng Aviation Technology (Sichuan) Co., Ltd., with an investment of 50 million yuan to support its low-altitude economy business [5] - Chunguang Technology has signed an investment development regulatory agreement for a project in Suzhou, with an expected initial investment of approximately 289 million yuan [5] - Fuliwang has begun shipping metal components such as robot reducers [6] - Xinyuren has successfully trial-produced halide solid electrolyte samples and completed the first round of electrochemical testing [7] - Southeast Network Frame has won the bid for the "Puyang Street Five Villages Joint Planning and Development Project," with a total bid amount of 1.686 billion yuan, accounting for 15% of the company's audited revenue for 2024 [7] - Heng Rui Medicine has received a clinical trial approval notice for HRS-4729 injection [8]